A boutique executive search and advisory firm built for the biopharmaceutical sector — serving the full spectrum from emerging biotechs to established large pharma.
Blake & Michaels is a boutique executive search and advisory firm serving the full spectrum of the biopharmaceutical sector — from emerging venture-backed biotechs and mid-sized development-stage companies to established large pharma organizations navigating leadership transitions.
We specialize in placing C-suite executives and functional heads at companies navigating critical inflection points: pre-IND, crossover rounds, Phase II readouts, pre-IPO structuring, and public company transitions. Our mandates span organizations of every scale — from first executive hires at Series A companies to C-suite upgrades at publicly traded large pharma.
Operating as a high-touch alternative to global firms, we deliver sector depth, board fluency, and disciplined execution without institutional bureaucracy. Search, to us, is not transactional — it is strategic risk management.
Blake & Michaels maintains active relationships across clinical KOLs and physician-scientists, venture syndicate members, and board directors in oncology, rare and orphan disease, and advanced modalities — giving us the proximity to surface candidates who are rarely visible through conventional search channels.
Whether our client is a Series A biotech structuring its first clinical team, a mid-sized company preparing for a crossover round, or a large pharma organization replacing a departing CMO, we bring the same discipline: calibrated success profiles, capital-aware strategy, and high-signal candidate evaluation.
Founded and led by Jason Stewart, Blake & Michaels brings deep sector expertise, active network relationships, and a disciplined approach to every engagement — without the institutional overhead or competing priorities of global search firms.
Jason maintains active relationships across clinical KOLs and physician-scientists, venture syndicate members, and board directors in oncology, rare and orphan disease, and advanced modalities. This proximity surfaces candidates who are rarely visible through conventional search channels — individuals whose expertise, timing, and trajectory align with the precise moment a company faces.
With experience spanning Series A biotechs to top-10 global pharma, Jason brings the same rigor to a first executive hire as to a C-suite upgrade at a publicly traded company: calibrated success profiles, capital-aware strategy, and high-signal candidate evaluation from a position of genuine sector fluency.
All initial conversations are confidential. If you are approaching an inflection point and believe leadership quality will determine your trajectory — we are ready to engage.